$214.00
0.240.11%
Ult. Agg.: Oct 21, 4:00 AM
$214.00
0.240.11%
Jazz Pharmaceuticals (JAZZ) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Jazz Pharmaceuticals (JAZZ) ha pubblicato l'ultima guidance il agosto 3, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $4.6B - $4.75B per il periodo.
Rispetto alle previsioni precedenti, Jazz Pharmaceuticals ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Jazz Pharmaceuticals ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Jazz Pharmaceuticals. 20
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $5.94 | $4.49 | $6.16 | $5.43 |
| Actual | $5.71 | $6.34 | $6.64 | $8.13 |
| Surprise | -3.87% | +41.2% | +7.79% | +49.7% |
| Revenue | ||||
| Estimate | $1.11B | $977.6M | $1.17B | $1.11B |
| Actual | $1.21B | $1.61B | $1.20B | $1.13B |
| Surprise | +9.06% | +64.6% | +2.21% | +1.89% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $3.18 | $6.39 | $5.23 | $5.68 |
| Revenue | ||||
| Consensus | $1.21B | $1.24B | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $5.71 | $5.94 | -3.87 % |
| Q1 | May 5, 2026 | $6.34 | $4.49 | 41.2 % |
| Q4 | Feb 24, 2026 | $6.64 | $6.16 | 7.79 % |
| Q3 | Nov 5, 2025 | $8.13 | $5.43 | 49.7 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $1.21B | $1.11B | 9.06 % |
| Q1 | May 5, 2026 | $1.61B | $977.61M | 64.6 % |
| Q4 | Feb 24, 2026 | $1.20B | $1.17B | 2.21 % |
| Q3 | Nov 5, 2025 | $1.13B | $1.11B | 1.89 % |